- Idera Pharmaceuticals (NASDAQ:IDRA) appoints Daniel Soland as Senior VP and chief operating officer, effective Jan. 4, 2021.
- Soland has been engaged as a consultant to Idera for nearly three years. Most recently, he served as CEO at uniQure N.V. and prior to that, Senior VP & COO of ViroPharma.
- At Idera, Soland will be responsible for commercial strategy manufacturing, NDA filing relating to the company's pivotal trial, ILLUMINATE-301, which are currently expected in the first quarter of 2021.
- The company also announces the retirement of R. Clayton Fletcher, Senior VP of Business Development and Strategic Planning, at the end of this year.
- Stock +1% AH.